HIGHER BIOLOGICALLY EFFECTIVE DOSE OF RADIOTHERAPY IS ASSOCIATED WITH IMPROVED OUTCOMES FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CARCINOMA TREATED WITH CHEMORADIATION: AN ANALYSIS OF THE RADIATION THERAPY ONCOLOGY GROUP

被引:218
作者
Machtay, Mitchell [1 ]
Bae, Kyounghwa [2 ]
Movsas, Benjamin [3 ]
Paulus, Rebecca [2 ]
Gore, Elizabeth M. [4 ]
Komaki, Ritsuko [5 ]
Albain, Kathy [6 ]
Sause, William T. [7 ]
Curran, Walter J. [8 ]
机构
[1] Case Western Reserve Univ, Univ Hosp, Cleveland, OH 44106 USA
[2] Dept Stat, RTOG, Philadelphia, PA USA
[3] Henry Ford Hosp, Detroit, MI 48202 USA
[4] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Loyola Univ Chicago Stritch Sch Med, Maywood, IL USA
[7] LDS Hosp, Salt Lake City, UT USA
[8] Emory Univ, Atlanta, GA 30322 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2012年 / 82卷 / 01期
关键词
Radiation oncology; Advanced non-small-cell lung carcinoma; Chemoradiotherapy; Local-regional failure; Survival with respect to radiotherapy dose intensity; LEUKEMIA GROUP-B; PHASE-III TRIAL; HYPERFRACTIONATED RADIATION; CONCURRENT CHEMORADIATION; INDUCTION CHEMOTHERAPY; CONSOLIDATION DOCETAXEL; THORACIC RADIOTHERAPY; COMPETING RISK; FOLLOW-UP; CANCER;
D O I
10.1016/j.ijrobp.2010.09.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Patients treated with chemoradiotherapy for locally advanced non small-cell lung carcinoma (LA-NSCLC) were analyzed for local-regional failure (LRF) and overall survival (OS) with respect to radiotherapy dose intensity. Methods and Materials: This study combined data from seven Radiation Therapy Oncology Group (RTOG) trials in which chemoradiotherapy was used for LA-NSCLC: RTOG 88-08 (chemoradiation arm only), 90-15, 91-06, 92-04, 93-09 (nonoperative arm only), 94-10, and 98-01. The radiotherapeutic biologically effective dose (BED) received by each individual patient was calculated, as was the overall treatment time-adjusted BED (tBED) using standard formulae. Heterogeneity testing was done with chi-squared statistics, and weighted pooled hazard ratio estimates were used. Cox and Fine and Gray's proportional hazard models were used for OS and LRF, respectively, to test the associations between BED and tBED adjusted for other covariates. Results: A total of 1,356 patients were analyzed for BED (1,348 for tBED). The 2-year and 5-year OS rates were 38% and 15%, respectively. The 2-year and 5-year LRF rates were 46% and 52%, respectively. The BED (and tBED) were highly significantly associated with both OS and LRF, with or without adjustment for other covariates on multivariate analysis (p < 0.0001). A 1-Gy BED increase in radiotherapy dose intensity was statistically significantly associated with approximately 4% relative improvement in survival; this is another way of expressing the finding that the pool-adjusted hazard ratio for survival as a function of BED was 0.96. Similarly, a 1-Gy tBED increase in radiotherapy dose intensity was statistically significantly associated with approximately 3% relative improvement in local-regional control; this is another way of expressing the finding that the pool-adjusted hazard ratio as a function of tBED was 0.97. Conclusions: Higher radiotherapy dose intensity is associated with improved local-regional control and survival in the setting of chemoradiotherapy. (C) 2012 Elsevier Inc.
引用
收藏
页码:425 / 434
页数:10
相关论文
共 42 条
[1]   Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial [J].
Albain, Kathy S. ;
Swann, R. Suzanne ;
Rusch, Valerie W. ;
Turrisi, Andrew T., III ;
Shepherd, Frances A. ;
Smith, Colum ;
Chen, Yuhchyau ;
Livingston, Robert B. ;
Feins, Richard H. ;
Gandara, David R. ;
Fry, Willard A. ;
Darling, Gail ;
Johnson, David H. ;
Green, Mark R. ;
Miller, Robert C. ;
Ley, Joanne ;
Sause, Willliam T. ;
Cox, James D. .
LANCET, 2009, 374 (9687) :379-386
[2]  
American College of Radiology, 2009, 0617 RTOG AM COLL RA
[3]  
[Anonymous], P AM SOC CLIN ONCOL
[4]   Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol [J].
Belani, CP ;
Choy, H ;
Bonomi, P ;
Scott, C ;
Travis, P ;
Haluschak, J ;
Curran, WJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5883-5891
[5]  
Bradley J, 2009, J THOR ONCOL S
[6]  
Bradley JD, 2005, J CLIN ONCOL S, P7063
[7]   Phase I/II results of RTOG L-0117; a phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with inoperable NSCLC [J].
Bradley, Jeffrey D. ;
Graham, Mary V. ;
Moughan, Jennifer ;
Byhardt, Roger ;
Govindan, Ramaswamy ;
Fowler, Jack ;
Purdy, James ;
Michalski, Jeff M. ;
Gore, Elizabeth ;
Choy, Hak .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) :S476-S476
[8]  
Byhardt R, 1995, CANCER, V75, P2237
[9]   A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (A Vanderbilt cancer center affiliate network study) [J].
Choy, H ;
Devore, RF ;
Hande, KR ;
Porter, LL ;
Rosenblatt, P ;
Yunus, F ;
Schlabach, L ;
Smith, C ;
Shyr, Y ;
Johnson, DH .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (04) :931-937
[10]  
Collett D, 1994, MODELLING SURVIVAL D